KBY Biotech Indexv0.0.34
Search
← Pipeline|HAR-9296

HAR-9296

Phase 1
By Harmony Bio
Source: Trial-derived·Trials: 1
Modality
mAb
MOA
CD47i
Target
CD19
Pathway
RAS/MAPK
HNSCCCeliacCholangiocarcinoma
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
Phase 1Current
NCT07196051
2,038 pts·Cholangiocarcinoma
2017-05→TBD·Terminated
2,038 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Termina…
Terminated|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07196051Phase 1CholangiocarcinomaTerminated2038PASI75
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-8662PfizerNDA/BLACD19GLP-1ag
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
ZenonesiranGSKPreclinicalDLL3CD47i
AMG-7379AmgenPreclinicalDLL3CD47i